$0.95
5.99% day before yesterday
Nasdaq, Sep 06, 10:16 pm CET
ISIN
US81750R1023
Symbol
MCRB
Sector
Industry

Seres Therapeutics Inc Stock price

$0.95
-0.06 5.55% 1M
-0.06 5.55% 6M
-0.45 31.86% YTD
-2.24 70.10% 1Y
-5.73 85.72% 3Y
-2.72 74.01% 5Y
-50.45 98.14% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
+0.05 5.99%
ISIN
US81750R1023
Symbol
MCRB
Sector
Industry

Key metrics

Market capitalization $145.36m
Enterprise Value $286.76m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 775.03
P/S ratio (TTM) P/S ratio 392.86
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -99.71%
Revenue (TTM) Revenue $370.00k
EBIT (operating result TTM) EBIT $-163.05m
Free Cash Flow (TTM) Free Cash Flow $-184.64m
Cash position $71.23m
EPS (TTM) EPS $-1.18
P/E forward negative
P/S forward 5.63
EV/Sales forward 11.10
Short interest 15.44%
Show more

Is Seres Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Seres Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Seres Therapeutics Inc forecast:

3x Buy
50%
2x Hold
33%
1x Sell
17%

Analyst Opinions

6 Analysts have issued a Seres Therapeutics Inc forecast:

Buy
50%
Hold
33%
Sell
17%

Financial data from Seres Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
0.37 0.37
100% 100%
100%
- Direct Costs 11 11
19% 19%
2,951%
-11 -11
109% 109%
-2,851%
- Selling and Administrative Expenses 47 47
27% 27%
12,678%
- Research and Development Expense 95 95
47% 47%
25,589%
-152 -152
19% 19%
-41,116%
- Depreciation and Amortization 11 11
19% 19%
2,951%
EBIT (Operating Income) EBIT -163 -163
16% 16%
-44,068%
Net Profit -162 -162
6% 6%
-43,814%

In millions USD.

Don't miss a Thing! We will send you all news about Seres Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Seres Therapeutics Inc Stock News

Neutral
Seeking Alpha
25 days ago
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Carlo Tanzi - IR Eric Shaff - CEO Lisa von Moltke - Chief Medical Officer Marella Thorell - CFO Matthew Henn - EVP, Chief Scientific Officer Teresa Young - EVP, Chief Commercial & Strategy Officer, Conference Call Participants Tessa Romero - JPMorgan Chase & Co. Edward Tentho...
Neutral
GlobeNewsWire
about one month ago
Upon closing, Seres to receive $175M cash infusion, including an upfront payment, prepayment of a future commercial milestone payment, and an equity investment in Seres common stock, less approximately $20M in settlement of net obligations between the Parties; anticipated deal closing in the next 90 days
Neutral
GlobeNewsWire
about one month ago
CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on August 13, 2024 at 8:30 a.m. ET to discuss second quarter 2024 financial results and provide business updates.
More Seres Therapeutics Inc News

Company Profile

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Head office United States
CEO Eric Shaff
Employees 233
Founded 2010
Website www.serestherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today